W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

News

01 August, 2024

Opinion of the Transparency Council – doxazosinum (1 mg, 2 mg)

01 August, 2024

Opinion of the Transparency Council – valgancyclovir

01 August, 2024

Position of the Transparency Council – Daraprim

01 August, 2024

Opinion of the Transparency Council – tocilizumab

01 August, 2024

Opinion of the Transparency Council – rituximab

01 August, 2024

Communication of the meeting of Transparency Council No. 32/2024 on 29 July 2024

30 July, 2024

Recommendation of the President – Tecentriq (atezolizumab)

30 July, 2024

Recommendation of the President – Lynparza (olaparib)

30 July, 2024

The Transparency Council meeting 33/2024 on 5 August 2024

29 July, 2024

Recommendation of the President – Ilaris (canakinumab)

29 July, 2024

Recommendation of the President – Fintepla (fenfluramine)

29 July, 2024

Opinion of the President – HPP future without diabetes

26 July, 2024

Recommendation of the President – Cablivi (caplacizumab)

26 July, 2024

Recommendation of the President – Glycosade

26 July, 2024

Recommendation of the President – Keytruda (pembrolizumab)

26 July, 2024

Recommendation of the President – Cabomety (cabozantinib)

26 July, 2024

Recommendation of the President – Opdivo (nivolumab)

25 July, 2024

Opinion of the Transparency Council – Future without diabetes

25 July, 2024

Opinion of the Transparency Council – Program for prevention and early detection of eye defects in children aged 14 years residing in the municipality of Opalenica for 2024-2026

25 July, 2024

Opinion of the Transparency Council – Prevention and early detection of testicular cancer among men aged 20-39 years, residing in the Wielkopolska province for 2024-2025

25 July, 2024

Position of the Transparency Council – on the validity of the qualification of the service Gyroscopic Stereotactic Teleradiotherapy (TSZ) using the novel ZAP-X device

25 July, 2024

Position of the Transparency Council – Cablivi (caplacizumab)

25 July, 2024

Position of the Transparency Council – Ilaris (canakinumab)

25 July, 2024

Position of the Transparency Council – Tecentriq (atezolizumab)

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑